Soledad Jorge1, June Y Hou2, Ana I Tergas3, William M Burke2, Yongmei Huang4, Jim C Hu5, Cande V Ananth6, Alfred I Neugut7, Dawn L Hershman7, Jason D Wright8. 1. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, United States; New York Presbyterian Hospital, United States. 2. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, United States; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, United States; New York Presbyterian Hospital, United States. 3. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, United States; Department of Epidemiology, Mailman School of Public Health, Columbia University, United States; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, United States; New York Presbyterian Hospital, United States. 4. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, United States. 5. Department of Urology, Weill Cornell Medical College, United States; New York Presbyterian Hospital, United States. 6. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, United States; Department of Epidemiology, Mailman School of Public Health, Columbia University, United States. 7. Department of Medicine, Columbia University College of Physicians and Surgeons, United States; Department of Epidemiology, Mailman School of Public Health, Columbia University, United States; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, United States; New York Presbyterian Hospital, United States. 8. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, United States; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, United States; New York Presbyterian Hospital, United States. Electronic address: jw2459@columbia.edu.
Abstract
OBJECTIVES: While lymphvascular space invasion (LVSI) is a risk factor for nodal metastasis in endometrial cancer, the magnitude of risk is poorly described. We examined the risk of nodal metastasis associated with LVSI for various combinations of tumor grade and depth of invasion and examined the effect of LVSI on survival. METHODS: We identified patients with T1A (<50% myoinvasion) and T1B (>50% myoinvasion) endometrioid adenocarcinomas of the endometrium diagnosed between 2010 and 2012 and recorded in the National Cancer Database. The risk of nodal metastasis associated with LVSI stratified by grade and stage is reported. The association of LVSI and survival was examined using Kaplan-Meier analyses and Cox proportional hazards models. RESULTS: We identified 25,907 patients, including 3928 (15.2%) with LVSI. Among patients with LVSI, 21.0% had positive lymph nodes, compared to 2.1% in patients without LVSI (P<0.0001). In analyses stratified by stage and grade, LVSI was associated with increased risks of LN metastasis by a magnitude of 3 to over 10-fold. In a multivariable model controlling for clinical and demographic characteristics, the risk ratio of nodal disease with LVSI was 9.29 (95% CI, 7.29-11.84) for T1A tumors and 4.64 (95% CI 3.99-5.39) for T1B tumors. LVSI was associated with decreased survival even after adjustment for the presence of lymph node metastases (HR=1.92, 95% CI 1.56-2.36). CONCLUSIONS: LVSI is independently associated with lymph node metastases in women with apparent early-stage endometrial cancer and an independent predictor of survival even after adjustment for the presence of lymph node metastases.
OBJECTIVES: While lymphvascular space invasion (LVSI) is a risk factor for nodal metastasis in endometrial cancer, the magnitude of risk is poorly described. We examined the risk of nodal metastasis associated with LVSI for various combinations of tumor grade and depth of invasion and examined the effect of LVSI on survival. METHODS: We identified patients with T1A (<50% myoinvasion) and T1B (>50% myoinvasion) endometrioid adenocarcinomas of the endometrium diagnosed between 2010 and 2012 and recorded in the National Cancer Database. The risk of nodal metastasis associated with LVSI stratified by grade and stage is reported. The association of LVSI and survival was examined using Kaplan-Meier analyses and Cox proportional hazards models. RESULTS: We identified 25,907 patients, including 3928 (15.2%) with LVSI. Among patients with LVSI, 21.0% had positive lymph nodes, compared to 2.1% in patients without LVSI (P<0.0001). In analyses stratified by stage and grade, LVSI was associated with increased risks of LN metastasis by a magnitude of 3 to over 10-fold. In a multivariable model controlling for clinical and demographic characteristics, the risk ratio of nodal disease with LVSI was 9.29 (95% CI, 7.29-11.84) for T1A tumors and 4.64 (95% CI 3.99-5.39) for T1B tumors. LVSI was associated with decreased survival even after adjustment for the presence of lymph node metastases (HR=1.92, 95% CI 1.56-2.36). CONCLUSIONS:LVSI is independently associated with lymph node metastases in women with apparent early-stage endometrial cancer and an independent predictor of survival even after adjustment for the presence of lymph node metastases.
Authors: Justine M Briët; Harry Hollema; Nathalie Reesink; Jan G Aalders; Marian J E Mourits; Klaske A ten Hoor; Elisabeth Pras; H Marike Boezen; Ate G J van der Zee; Hans W Nijman Journal: Gynecol Oncol Date: 2005-03 Impact factor: 5.482
Authors: Sharyn N Lewin; Thomas J Herzog; Nicanor I Barrena Medel; Israel Deutsch; William M Burke; Xuming Sun; Jason D Wright Journal: Obstet Gynecol Date: 2010-11 Impact factor: 7.661
Authors: O Gemer; A Ben Arie; T Levy; M Gdalevich; M Lorian; F Barak; E Anteby; O Lavie Journal: Eur J Surg Oncol Date: 2007-02-20 Impact factor: 4.424
Authors: Nicanor I Barrena Medel; Thomas J Herzog; Israel Deutsch; William M Burke; Xuming Sun; Sharyn N Lewin; Jason D Wright Journal: Am J Obstet Gynecol Date: 2011-01-17 Impact factor: 8.661
Authors: M Nishiya; N Sakuragi; H Hareyama; Y Ebina; M Furuya; M Oikawa; R Yamamoto; T Fujino; S Fujimoto Journal: Int J Cancer Date: 1998-10-23 Impact factor: 7.396
Authors: Sang Il Kim; Joo Hee Yoon; Sung Jong Lee; Min Jong Song; Jin Hwi Kim; Hae Nam Lee; Gyul Jung; Ji Geun Yoo Journal: Int J Med Sci Date: 2021-06-01 Impact factor: 3.738